Podcast: Play in new window | Download (Duration: 34:13 — 78.3MB)

Subscribe: Apple Podcasts | Spotify | RSS

In this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, is joined by Andy Meyerson, Managing Director, and Daniel Brog, Senior Vice President, for an insightful discussion on the implications of the 2024 U.S. election results for the biotech industry.

The conversation delves into:

• What Trump’s victory could mean for the biotech sector.
• The potential impact on the HHS and FDA under RFK’s leadership.
• How figures like Elon Musk and Vivek Ramaswamy might influence healthcare policy (DOGE dynamics).

We take a balanced approach, covering the potential positive and negative outcomes, implications, and our perspectives on these topics. Our analysis is based on actual statements made and prior activities, focusing specifically on the impacts for biotech. While we aim to minimize bias, we acknowledge that personal perspectives inevitably influence conclusions. Please note this was recorded Friday, November 23, before the announcements of the FDA Commissioner, Surgeon General, and Head of the CDC later that day.

Join us as we explore how these political outcomes could shape the future of biotech and healthcare innovation. We welcome your thoughts and look forward to engaging in further discussions as events unfold.

Email us at ceo@locustwalk.com to share your insights or questions.

Subscribe or follow Biotalk on Apple Podcasts | Spotify.